# Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase

> **NCT06119269** · — · RECRUITING · sponsor: **University of Pisa** · enrollment: 100 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia, Chronic Phase

## Interventions

- **DIAGNOSTIC_TEST:** Therapeutic drug monitoring
- **DIAGNOSTIC_TEST:** Molecular Response

## Key facts

- **NCT ID:** NCT06119269
- **Lead sponsor:** University of Pisa
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-02
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06119269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06119269, "Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06119269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*